Goldman Sachs Group (GS)
549.36
-10.20 (-1.82%)
NYSE · Last Trade: May 6th, 4:21 PM EDT
Detailed Quote
Previous Close | 559.56 |
---|---|
Open | 549.60 |
Bid | 548.76 |
Ask | 556.00 |
Day's Range | 547.06 - 557.44 |
52 Week Range | 437.37 - 672.19 |
Volume | 2,874,838 |
Market Cap | 188.68B |
PE Ratio (TTM) | 12.76 |
EPS (TTM) | 43.0 |
Dividend & Yield | 12.00 (2.18%) |
1 Month Average Volume | 3,225,268 |
Chart
About Goldman Sachs Group (GS)
Goldman Sachs Group is a leading global investment banking, securities, and investment management firm that provides a wide range of financial services to a diverse client base, including corporations, financial institutions, governments, and individuals. The company engages in various activities, including financial advisory services, underwriting of capital market transactions, asset management, and market making in securities and commodities. It is known for its expertise in mergers and acquisitions, risk management, and investment strategy, leveraging its extensive research capabilities and global reach to deliver innovative solutions in an ever-evolving financial landscape. Read More
News & Press Releases
Expectations are low for the media bellwether heading into an important financial update on Wednesday.
Via The Motley Fool · May 6, 2025
There are plenty of good ones to choose from, but these three are all undervalued, leaving them ripe for a lot of bullishness sooner than later.
Via The Motley Fool · May 6, 2025
Shares of healthcare services company Sotera Health (NASDAQ:)
jumped 5.9% in the pre-market session after Goldman Sachs analyst Matthew Sykes upgraded the stock from Neutral to Buy and raised the price target from $14 to $17. Sykes emphasized that SHC's consistent exposure to the commercial pharmaceutical and medical device sectors, both of which are considered essential and relatively insulated from economic cycles, positions the company as a more compelling investment amid growing macroeconomic uncertainty.
Via StockStory · May 5, 2025
Goldman Sachs upgrades Sotera Health to Buy, citing tariff immunity, legal clarity, and exposure to Medtech innovation for future growth.
Via Benzinga · May 5, 2025
Proximo Capital's Founder & Managing Director, James Mendelsohn, an esteemed Eagle Scout, will receive the prestigious NESA Outstanding Eagle Scout Award
Via PRUnderground · May 5, 2025
OPEC+ hike in production and Goldman's oil price forecast decrease led to a selloff in US energy stocks. Brent and WTI may drop to $40s by 2026.
Via Benzinga · May 5, 2025
Amazon beat Q1 expectations and analysts are very much bullish, with some price targets calling for almost 50% upside from current levels.
Via MarketBeat · May 5, 2025
Today, with the rapid development of the blockchain and digital asset industries, trust crises follow closely. From the platform’s disappearance and the black box of assets to the loss of user assets, an increasing number of investors have begun to realize that a truly reliable digital financial platform is not only technologically leading but also must have long-term support in terms of systems, compliance and security. It is precisely under such an era background that RBH Infinity Exchange, as a new generation of digital asset trading platform, shoulders the responsibility of rebuilding user trust and financial order. Since its establishment in 2021, RBH has always adhered to the core concept of “true value, technology-driven, and trust-based”, and is committed to building a global digital asset infrastructure that combines security, transparency, and international compliance.
Via Binary News Network · May 5, 2025
Apprehensions regarding deal closure, Trump’s tariff threat, earnings anxiety and a delayed product launch led to a spike in activity levels for these stocks.
Via Stocktwits · May 5, 2025
New York, US, 2nd May 2025, ZEX PR WIRE, In an Read more
Via Zexprwire · May 2, 2025
Via The Motley Fool · May 2, 2025
Eli Lilly's Zepbound loses CVS coverage to Wegovy, prompting analyst debate on pricing pressures and long-term obesity market potential.
Via Benzinga · May 2, 2025
Some believe that the rise in gold is far from over. With $4,000 evoked, see these three investments with big variations in possible risk and return outcomes.
Via MarketBeat · May 2, 2025
Goldman Sachs said the expected drop in Q2 attendance may have to do with the Easter shift to April, potentially pushing travel plans from March.
Via Stocktwits · May 2, 2025
AI-Driven DeFi Platform Aims to Reshape the Future of Intelligent, Decentralized Asset Management
Via Binary News Network · May 2, 2025
Goldman Sachs analyst expects GM's FY25 guidance cut due to tariff uncertainty. Current policy could cost GM $4-5 billion, leading to revised EPS.
Via Benzinga · May 1, 2025
Eric Glass, CEO and founder at Clarion Call Capital, joined me on a recent episode of The Impact to discuss how Clarion Call Capital is investing in an
Via Equities.com · May 1, 2025
Goldman Sachs lowers its price target to $85 from $103, with several other analysts making similar downward revisions.
Via Stocktwits · May 1, 2025
President Donald Trump deflects blame for the U.S. economy's 0.3% contraction in the first quarter onto his predecessor, despite clear evidence indicating otherwise.
Via Benzinga · April 30, 2025
Via Benzinga · April 30, 2025
Goldman Sachs keeps Neutral on Pfizer, citing unclear product growth plans and focus on M&A amid changing market valuations and national security concerns.
Via Benzinga · April 30, 2025
Starbucks (NASDAQ: SBUX) missed Q2 FY25 expectations, prompting Goldman Sachs to downgrade the stock to Neutral with a lower price target of $85. Analysts cite soft North America sales, declining consumer sentiment, and ongoing macroeconomic pressures as key concerns.
Via Benzinga · April 30, 2025